Key Points: I think that an imminent press release dealing with topline results from an interim look at the ZUMA-1 trial will not have much meaningful data even though it is highly anticipated by investors. We will have to wait for the full data set that will be presented at American Society of hematology (ASH) … Continue reading Kite Pharma Part 4: A Preview of Highly Anticipated Results from Interim Look at ZUMA-1 (KITE, Neutral, $54.95)